As FTT's process we have been told is far less expensive than current standard of care......why isn't it still a potentially very profitable commercial proposition ?
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025